CAR-T細胞療法の世界市場2023-2030

世界のCAR-T細胞療法市場は、予測期間中にCAGR 12.0％で成長すると推定されます。市場成長の主な要因としては、世界のがんの有病率の高さ、細胞・遺伝子治療に対するFDA承認の増加などが挙げられます。世界保健機関（WHO）によると、世界のがん負担は2018年に1810万人の新規症例と960万人の死亡に上ったと推定されています。2018年には約4,380万人ががんと共に生き、過去5年以内に診断されました。このようながんの有病率の上昇は、CAR-T細胞療法の開発に起因しています。CAR-T細胞療法は、免疫系の一部であるT細胞を特別に変化させてがんを攻撃する免疫療法の一種です。現在、がんの治療薬として承認されているCAR-T細胞療法は2種類あり、YescartaとKymriahです。Yescartaは2017年10月、びまん性大細胞型B細胞リンパ腫（DLBCL）の治療薬として米国FDAに承認されました。Kymriahは2018年5月、特定の種類の非ホジキンリンパ腫を有する成人の治療薬として米国FDAに承認されました。Kymriahは小児および若年成人の白血病の治療薬としても承認されています。臨床試験では、Kymriahによる治療を受けた若年成人および小児の80％以上ががん寛解を達成しました。

リンパ腫やその他の血液がんを治療するCAR-T細胞療法の初期結果は有望です。標準治療に失敗した、あるいは血液がんが再発した複数の患者が、CAR-T細胞療法で完全な成功を収めました。その結果、米国FDAは細胞療法と遺伝子療法の承認に力を入れています。いくつかのCAR-T細胞療法は、乳がん、大腸がん、血液がんの治療のために臨床段階にあります。これらの新しい治療法の発売は、市場成長の機会となると思われます。

セグメント別の展望

CD19標的抗原が世界のCAR-T細胞療法市場で最大のシェアを占める

標的抗原の中で、CD19は2018年にかなりの成長を示しています。市場で入手可能なYescartaやKymriahを含むCAR-T療法はいずれも、白血病やリンパ腫を含むB細胞に影響を及ぼすいくつかの形態のがんの治療のためにCD19を標的としています。これらのCAR-T細胞療法に関連する利点は臨床試験で示されており、研究者やバイオテクノロジー企業がCD19標的領域で事業を行うきっかけとなっています。例えば、2019年11月、テキサス大学MDアンダーソンがんセンターと武田薬品工業株式会社は、独占的ライセンス契約を締結しました。武田薬品工業株式会社は、IL-15で「武装」した血液由来のCAR指向性ナチュラルキラー（CAR NK）細胞療法の開発に関する独占的ライセンス契約および研究契約を締結し、B細胞悪性腫瘍およびその他のがんを治療することを宣言しました。本契約により、武田薬品は、MDアンダーソンのCAR NKプラットフォームへのアクセス権、およびaB細胞成熟抗原（BCMA）標的CAR NK細胞療法やCD19標的CAR NK細胞療法など最大4つのプログラムの独占的開発・販売権を取得します。CD19標的抗原CAR-T細胞療法の臨床試験が開始されつつあり、市場成長の大きな機会となっています。

地域別展望

世界のCAR-T細胞療法市場は、北米（米国とカナダ）、欧州（イタリア、スペイン、ドイツ、フランス、その他）、アジア太平洋地域（インド、中国、日本、韓国、その他）、世界のその他の地域（中東とアフリカ、ラテンアメリカ）など、地域別にさらに細分化されています。市場は、要求に応じて特定の地域または国レベルで分析することができます。北米は、がんの有病率が高く、ライフサイエンス研究において大きなシェアを占めていることから、同市場において最大のシェアを占めています。Gilead Sciences, Inc.、Pfizer, Inc.、Bristol-Myers Squibb Co.などの大手企業が存在することが、この地域における市場成長の可能性をもたらしています。臨床試験での有効性から米国FDAによる細胞治療の承認が増加していることも、同地域の市場成長に大きな機会をもたらしています。

目次

第1章 レポートの概要

• 調査方法とツール
• 市場内訳
  • セグメント別
  • 地域別

第2章 市場概要と洞察

• 調査範囲
• アナリストの洞察と現在の市場動向
  • 主な調査結果
  • 推奨事項
  • 結論

第3章 競合情勢

• 主要企業分析
• Novartis International AG
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• Gilead Sciences, Inc.
  • 会社概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• Pfizer, Inc.
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• Bristol-Myers Squibb Co.
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• Takeda Pharmaceutical Co. Ltd.
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向

第4章 市場セグメンテーション

• CAR-T細胞療法の世界市場：用途別
  • 非ホジキンリンパ腫
  • 急性リンパ性白血病
  • その他（多発性骨髄腫、ホジキンリンパ腫、乳がん）
• CAR-T細胞療法の世界市場：標的抗原別
  • CD19
  • CD22
  • その他（CD123、CD33、BCMA）

第5章 地域別分析

• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • イタリア
  • スペイン
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • その他アジア太平洋地域
• 世界のその他の地域

第6章 企業プロファイル

• Amgen Inc.
• Autolus Therapeutics plc
• Bluebird Bio, Inc.
• Bristol-Myers Squibb Co.
• CARsgen Therapeutics Co., Ltd.
• Cellectis SA
• Celyad SA
• Gilead Sciences, Inc.
• Intellia Therapeutics, Inc.
• Janssen Global Services, LLC（a Subsidiary of Johnson & Johnson）
• LesLaboratoiresServier, SAS
• Mustang Bio
• Nanjing Legend Biotechnology Co., Ltd.
• Noile-Immune Biotech Inc.
• Novartis International AG
• Pfizer, Inc.
• Precigen, Inc.
• Sangamo Therapeutics, Inc.
• Sorrento Therapeutics, Inc.
• Takeda Pharmaceutical Co. Ltd.

LIST OF TABLES

• 1. GLOBAL CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030($ MILLION)
• 2. GLOBAL CAR T CELL THERAPY IN NON-HODGKIN LYMPHOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030($ MILLION)
• 3. GLOBAL CAR T CELL THERAPY IN ACUTE LYMPHOCYTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030($ MILLION)
• 4. GLOBAL CAR T CELL THERAPY IN OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030($ MILLION)
• 5. GLOBAL CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY TARGET ANTIGEN, 2022-2030($ MILLION)
• 6. GLOBAL CD19 TARGETED CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030($ MILLION)
• 7. GLOBAL CD22 TARGETED CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030($ MILLION)
• 8. GLOBAL OTHER TARGETED CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030($ MILLION)
• 9. GLOBAL CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2022-2030($ MILLION)
• 10. NORTH AMERICAN CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030($ MILLION)
• 11. NORTH AMERICAN CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030($ MILLION)
• 12. NORTH AMERICAN CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY TARGET ANTIGEN, 2022-2030($ MILLION)
• 13. EUROPEAN CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030($ MILLION)
• 14. EUROPEAN CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030($ MILLION)
• 15. EUROPEAN CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY TARGET ANTIGEN, 2022-2030($ MILLION)
• 16. ASIA-PACIFIC CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030($ MILLION)
• 17. ASIA-PACIFIC CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030($ MILLION)
• 18. ASIA-PACIFIC CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY TARGET ANTIGEN, 2022-2030($ MILLION)
• 19. REST OF THE WORLD CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030($ MILLION)
• 20. REST OF THE WORLD CAR T CELL THERAPY MARKET RESEARCH AND ANALYSIS BY TARGET ANTIGEN, 2022-2030($ MILLION)

LIST OF FIGURES

• 1. GLOBAL CAR T CELL THERAPY MARKET SHARE BY APPLICATION, 2022 VS 2030 (%)
• 2. GLOBAL CAR T CELL THERAPY MARKET SHARE BY TARGET ANTIGEN, 2022 VS 2030 (%)
• 3. GLOBAL CAR T CELL THERAPY MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 4. GLOBAL CAR T CELL THERAPY IN NON-HODGKIN LYMPHOMA MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 5. GLOBAL CAR T CELL THERAPY IN ACUTE LYMPHOCYTIC LEUKEMIA MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 6. GLOBAL CAR T CELL THERAPY IN OTHER APPLICATIONS MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 7. GLOBAL CD19 TARGETED CAR T CELL THERAPY MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 8. GLOBAL CD22 TARGETED CAR T CELL THERAPY MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 9. GLOBAL OTHER TARGETED CAR T CELL THERAPY MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 10. US CAR T CELL THERAPY MARKET SIZE, 2022-2030 ($ MILLION)
• 11. CANADA CAR T CELL THERAPY MARKET SIZE, 2022-2030 ($ MILLION)
• 12. UK CAR T CELL THERAPY MARKET SIZE, 2022-2030 ($ MILLION)
• 13. FRANCE CAR T CELL THERAPY MARKET SIZE, 2022-2030 ($ MILLION)
• 14. GERMANY CAR T CELL THERAPY MARKET SIZE, 2022-2030 ($ MILLION)
• 15. ITALY CAR T CELL THERAPY MARKET SIZE, 2022-2030 ($ MILLION)
• 16. SPAIN CAR T CELL THERAPY MARKET SIZE, 2022-2030 ($ MILLION)
• 17. ROE CAR T CELL THERAPY MARKET SIZE, 2022-2030 ($ MILLION)
• 18. INDIA CAR T CELL THERAPY MARKET SIZE, 2022-2030 ($ MILLION)
• 19. CHINA CAR T CELL THERAPY MARKET SIZE, 2022-2030 ($ MILLION)
• 20. JAPAN CAR T CELL THERAPY MARKET SIZE, 2022-2030 ($ MILLION)
• 21. REST OF ASIA-PACIFIC CAR T CELL THERAPY MARKET SIZE, 2022-2030 ($ MILLION)
• 22. REST OF THE WORLD CAR T CELL THERAPY MARKET SIZE, 2022-2030 ($ MILLION)

Global CAR T cell therapy market is estimated to grow at a CAGR of 12.0% during the forecast period. The major factors contributing to the growth of the market include a significant prevalence of cancer across the globe and rising FDA approvals for cell and gene therapy. As per the World Health Organization (WHO), the global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018. Around 43.8 million people were living with cancer in 2018 and were diagnosed within the last 5 years. This rising prevalence of cancer is attributed to the development of CAR T cell therapy. It is a form of immunotherapy that utilizes specially altered T cells, a part of the immune system to attack cancer. There are currently two CAR T cell therapies approved for the treatment of cancer, which include Yescarta and Kymriah. Yescarta was approved by the US FDA in October 2017, for the treatment of diffuse large B-cell lymphoma (DLBCL). Kymriah was approved by the US FDA in May 2018, for the treatment of adults with certain kinds of non-Hodgkin lymphoma. Kymriah is also approved for the treatment of children and young adults with leukemia. In clinical trials, more than 80% of young adults and children treated with Kymriah achieved cancer remission.

Early results of CAR T-cell therapy to treat lymphoma and other blood cancers are promising. Multiple patients with failed standard treatments or whose blood cancers returned achieved complete success with CAR T cell therapy. As a result, the US FDA is focusing on the approvals of cell and gene therapies. Several CAR T cell therapies are in clinical phases for the treatment of breast cancer, colorectal cancer, and blood cancer. The launch of these novel therapies will likely offer an opportunity for the growth of the market.

Segmental Outlook

The global CAR T cell therapy market is segmented based on application and target antigen. Based on application, the market is classified into non-Hodgkin lymphoma, acute lymphocytic leukemia, and others. Based on target antigen, the market is classified into CD19, CD22, and others.

CD19 target antigen held the largest share in the global CAR T cell therapy market

Among target antigens, CD19 has witnessed considerable growth in 2018. Both CAR-T therapies, including Yescarta and Kymriah available in the market target CD19 for the treatment of several forms of cancers affecting B cells, including leukemia and lymphoma. The advantages related to these CAR-T cell therapies have been shown in clinical trials that have led researchers and biotechnology firms to conduct operations in the CD19 target space. For instance, in November 2019, the University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Co. Ltd. declared an exclusive license agreement and research agreement for the development of blood-derived CAR-directed natural killer (CAR NK)-cell therapies, 'armored' with IL-15, to treat B-cell malignancies and other cancers. In terms of the agreement, Takeda will get access to the CAR NK platform of MD Anderson and the exclusive rights for the development and commercialization of up to four programs, such as aB-cell maturation antigen (BCMA)-targeted CAR NK-cell therapy and CD19-targeted CAR NK-cell therapy. The emerging clinical trials for CD19 targeted antigen CAR T cell therapy is providing enormous opportunity for the growth of the market.

Regional Outlook

The global CAR T cell therapy market is further segmented based on geography, including North America (the US and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa and Latin America). The market can be analyzed for a particular region or country level as per the requirement. North America held the largest share in the market owing to the significant prevalence of cancer and significant share in life science research in the region. The presence of major players, including Gilead Sciences, Inc., Pfizer, Inc., and Bristol-Myers Squibb Co. are offering scope for market growth in the region. Increasing US FDA approvals for cell therapy owing to its effectiveness in clinical trials is further providing enormous opportunities for the growth of the market in the region.

Market Players Outlook

The major players in the global CAR T cell therapy market include Novartis International AG, Gilead Sciences, Inc., Pfizer, Inc., Bristol-Myers Squibb Co., and Takeda Pharmaceutical Co. Ltd. These companies are significantly focusing on the development of cell-based therapies as it targets the tumors with more precision, as compared to chemo and radiation therapy. Several partnerships among companies have been reported for the development and commercialization of CAR T cell therapies. For instance, in May 2019, Kite, a Gilead Co., and Humanigen, Inc. declared a clinical partnership for conducting a Phase 1/2 study of lenzilumab, an investigational anti-GM-CSF monoclonal antibody, with Yescarta (axicabtagene ciloleucel) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This study aims to define the effect of lenzilumab on Yescarta safety. Kite will be responsible to conduct this study and act as a sponsor for the study.

Table of Contents

1. Report Summary

• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Geography

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Findings
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
• 3.2. Novartis International AG
  • 3.2.1. Overview
  • 3.2.2. Financial Analysis
  • 3.2.3. SWOT Analysis
  • 3.2.4. Recent Developments
• 3.3. Gilead Sciences, Inc.
  • 3.3.1. Overview
  • 3.3.2. Financial Analysis
  • 3.3.3. SWOT Analysis
  • 3.3.4. Recent Developments
• 3.4. Pfizer, Inc.
  • 3.4.1. Overview
  • 3.4.2. Financial Analysis
  • 3.4.3. SWOT Analysis
  • 3.4.4. Recent Developments
• 3.5. Bristol-Myers Squibb Co.
  • 3.5.1. Overview
  • 3.5.2. Financial Analysis
  • 3.5.3. SWOT Analysis
  • 3.5.4. Recent Developments
• 3.6. Takeda Pharmaceutical Co. Ltd.
  • 3.6.1. Overview
  • 3.6.2. Financial Analysis
  • 3.6.3. SWOT Analysis
  • 3.6.4. Recent Developments

4. Market Segmentation

• 4.1. Global CAR T Cell Therapy Market by Application
  • 4.1.1. Non-Hodgkin Lymphoma
  • 4.1.2. Acute Lymphocytic Leukemia
  • 4.1.3. Others (Multiple Myeloma, Hodgkin Lymphoma, and Breast Cancer)
• 4.2. Global CAR T Cell Therapy Market by Target Antigen
  • 4.2.1. CD19
  • 4.2.2. CD22
  • 4.2.3. Others (CD123, CD33, and BCMA)

5. Regional Analysis

• 5.1. North America
  • 5.1.1. US
  • 5.1.2. Canada
• 5.2. Europe
  • 5.2.1. UK
  • 5.2.2. Germany
  • 5.2.3. Italy
  • 5.2.4. Spain
  • 5.2.5. France
  • 5.2.6. Rest of Europe
• 5.3. Asia-Pacific
  • 5.3.1. China
  • 5.3.2. India
  • 5.3.3. Japan
  • 5.3.4. Rest of Asia-Pacific
• 5.4. Rest of the World

6. Company Profiles

• 6.1. Amgen Inc.
• 6.2. Autolus Therapeutics plc
• 6.3. Bluebird Bio, Inc.
• 6.4. Bristol-Myers Squibb Co.
• 6.5. CARsgen Therapeutics Co., Ltd.
• 6.6. Cellectis SA
• 6.7. Celyad SA
• 6.8. Gilead Sciences, Inc.
• 6.9. Intellia Therapeutics, Inc.
• 6.10. Janssen Global Services, LLC (a Subsidiary of Johnson & Johnson)
• 6.11. LesLaboratoiresServier, SAS
• 6.12. Mustang Bio
• 6.13. Nanjing Legend Biotechnology Co., Ltd.
• 6.14. Noile-Immune Biotech Inc.
• 6.15. Novartis International AG
• 6.16. Pfizer, Inc.
• 6.17. Precigen, Inc.
• 6.18. Sangamo Therapeutics, Inc.
• 6.19. Sorrento Therapeutics, Inc.
• 6.20. Takeda Pharmaceutical Co. Ltd.